Trial Profile
Medication adherence of NOACs in real world patients with Nonvalvular Atrial Fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Jun 2017
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary)
- Indications Embolism
- Focus Therapeutic Use
- 30 Jun 2017 New trial record